# ğŸ“… Daily Report - 2025-12-20

> ä»Šæ—¥ç­›é€‰å‡º **41** æ¡å†…å®¹ï¼Œæ¥è‡ª **2** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
DeCAFæŠ€æœ¯çªç ´æ€§åœ°æ­ç¤ºäº†èƒ°è…ºç™Œä¸­ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFï¼‰çš„å¤šç»´åº¦å¼‚è´¨æ€§ï¼Œå¹¶é˜æ˜å…¶åœ¨è‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—å“åº”ä¸­çš„ä½œç”¨ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- **è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«æ²»ç–—**ï¼šç ”ç©¶ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFï¼‰å¼‚è´¨æ€§å¯¹èƒ°è…ºç™Œè¿›å±•åŠå…ç–«æ²»ç–—å“åº”çš„å½±å“ï¼›æ¢ç´¢è„‚è´¨é©±åŠ¨çš„å…ç–«ä»£è°¢é€šè·¯åœ¨åµå·¢ç™Œè…¹è†œè½¬ç§»ä¸­å¢å¼ºå…ç–«æ²»ç–—çš„æ½œåŠ›ï¼›è§£æESR1çªå˜å¯¹ä¹³è…ºè‚¿ç˜¤å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒçš„è´¡çŒ®ã€‚
- **è¡°è€ä¸è¡¨è§‚é—ä¼ **ï¼šåˆ©ç”¨å•æ ¸ç”²åŸºåŒ–æµ‹åºæ­ç¤ºå¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ã€‚
- **åŸºå› ç»„ç¨³å®šæ€§ä¸ç»†èƒå‘¨æœŸ**ï¼šé˜æ˜Poloæ ·æ¿€é…¶Cdc5å’Œç£·é…¸é…¶Cdc14åœ¨æœ‰ä¸åˆ†è£‚ä¸­è°ƒæ§æ‹“æ‰‘å¼‚æ„é…¶IIä»‹å¯¼çš„å§å¦¹æŸ“è‰²å•ä½“è”ä¼šè§£èšçš„å…³é”®æœºåˆ¶ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- **ç©ºé—´è½¬å½•ç»„å­¦**ï¼šé¦–æ¬¡ç”¨äºè§£æè‚¿ç˜¤å¾®ç¯å¢ƒä¸­çš„ç»†èƒå¼‚è´¨æ€§ã€‚
- **å¤šç»„å­¦æ•´åˆ**ï¼šç»“åˆATAC-Seqä¸åŸºå› è¡¨è¾¾æµ‹åºï¼Œæ·±å…¥ç ”ç©¶èƒšèƒå‘è‚²è¿‡ç¨‹ä¸­çš„æŸ“è‰²è´¨è°ƒæ§ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ç§‘å­¦å®¶é¦–æ¬¡å‘ç°Tç»†èƒå—ä½“æ¿€æ´»å­˜åœ¨éšè—çš„å¼¹ç°§å¼è¿åŠ¨ï¼Œæœ‰æœ›æå‡ç™Œç—‡å…ç–«ç–—æ³•çš„æœ‰æ•ˆæ€§ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- SARS-CoV-2æ„ŸæŸ“å½±å“è‚ºç»†èƒé•¿é“¾éç¼–ç RNAï¼ˆlncRNAsï¼‰çš„m6Aç”²åŸºåŒ–ï¼Œé‡å¡‘æŠ—ç—…æ¯’ååº”ã€‚
- æ¶²ä½“æ´»æ£€ä¸­RNAç”²åŸºåŒ–æ ‡å¿—ç‰©å¯ä½œä¸ºè‚ºç™Œè¯Šæ–­çš„äº’è¡¥ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- çº³ç±³å­”æŠ€æœ¯RNAæµ‹åºæ­ç¤ºè¡€æ¶²ä¸­å°RNAçš„ç”²åŸºåŒ–ç‰¹å¾ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (38æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE311783 DeCAF é‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³» [ç©ºé—´è½¬å½•ç»„å­¦]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€regex:immuno(logy|therapy|suppression)ã€spatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributors : Xianlu L Peng ; Ian C McCabe ; Jen Jen YehSeries Type : OtherOrganism : Homo sapiensCancer-associated fibroblast (CAF) heterogeneity within pancreatic ductal adenocarcinoma (PDAC) has been previously assessed through single-cell RNA sequencing (scRNAseq) to discover distinct CAF populations such as myCAFs and iCAFs. While useful as a biological framework, no studies have conclusively and robustly demonstrated a correlation of CAF subpopulations with clinical prognosis or therapy response. We define restraining (rest) and promoting (pro) CAFs in patient samples that are both prognostic and predictive of therapy response in disparate tumor types. Using a single sample classifier, DeCAF, we uncover distinct clinical and spatial interactions between pro- and restCAF subtypes and basal-like and classical tumor subtypes that support tumor stroma crosstalk where basal-like tumors are enriched in proCAFs and classical tumors are enriched in restCAFs. Finally, we find striking differences in the immune contexture of pro- and restCAF tumors where restCAF dominant tumors are enriched in patients who respond to immune checkpoint inhibition (ICI) in two large clinical trials, and proCAF dominant tumors are enriched in patients who respond to myeloid inhibition. This work is the first to define CAF subtypes that are clinically robust, prognostic, predictive of immunotherapy response, and associate with tumor molecular subtype.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311783)

**2.** â­ **GSE169236 é€šè¿‡å•æ ¸ç”²åŸºåŒ–æµ‹åºç ”ç©¶å¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ [CP-9mo-m-023]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šagingã€sequencingã€epigeneticã€methylation
- ğŸ“ **æè¿°**ï¼šContributors : Wei Tian ; Anna Bartlett ; Jordan Altshul ; Rosa Gomez Castanon ; Joseph R Nery ; Jacinta D Lucero ; Julia K Osteen ; Huaming Chen ; M M Behrens ; Joseph R EckerSeries Type : Methylation profiling by high throughput sequencingOrganism : Mus musculusIllustrating aging effects on the epigenomic features of brain is critical to understand brain functional decline and neurodegeneration. Single nucleus methylation sequencing was applied to brain regions of both male and female mouse at the age of 2, 9 and 18 months. We use these data to identify the epigenomic changes with aging in mouse brains.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169236)

**3.** â­ **GSE169251 é€šè¿‡å•æ ¸ç”²åŸºåŒ–æµ‹åºç ”ç©¶å¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ [DHC-9mo-m-001]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šagingã€sequencingã€epigeneticã€methylation
- ğŸ“ **æè¿°**ï¼šContributors : Wei Tian ; Anna Bartlett ; Jordan Altshul ; Rosa Gomez Castanon ; Joseph R Nery ; Jacinta D Lucero ; Julia K Osteen ; Huaming Chen ; M M Behrens ; Joseph R EckerSeries Type : Methylation profiling by high throughput sequencingOrganism : Mus musculusIllustrating aging effects on the epigenomic features of brain is critical to understand brain functional decline and neurodegeneration. Single nucleus methylation sequencing was applied to brain regions of mouse at the age of 2, 9 and 18 months. We use these data to identify the epigenomic changes with aging in mouse brains.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169251)

**4.** â­ **GSE311788 DeCAF é‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³» [scRNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€regex:immuno(logy|therapy|suppression)ã€scRNA
- ğŸ“ **æè¿°**ï¼šContributors : Xianlu L Peng ; Ian C McCabe ; Jen Jen YehSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCancer-associated fibroblast (CAF) heterogeneity within pancreatic ductal adenocarcinoma (PDAC) has been previously assessed through single-cell RNA sequencing (scRNAseq) to discover distinct CAF populations such as myCAFs and iCAFs. While useful as a biological framework, no studies have conclusively and robustly demonstrated a correlation of CAF subpopulations with clinical prognosis or therapy response. We define restraining (rest) and promoting (pro) CAFs in patient samples that are both prognostic and predictive of therapy response in disparate tumor types. Using a single sample classifier, DeCAF, we uncover distinct clinical and spatial interactions between pro- and restCAF subtypes and basal-like and classical tumor subtypes that support tumor stroma crosstalk where basal-like tumors are enriched in proCAFs and classical tumors are enriched in restCAFs. Finally, we find striking differences in the immune contexture of pro- and restCAF tumors where restCAF dominant tumors are enriched in patients who respond to immune checkpoint inhibition (ICI) in two large clinical trials, and proCAF dominant tumors are enriched in patients who respond to myeloid inhibition. This work is the first to define CAF subtypes that are clinically robust, prognostic, predictive of immunotherapy response, and associate with tumor molecular subtype.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311788)

**5.** â­ **GSE310957 DeCAF é‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³» [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€regex:immuno(logy|therapy|suppression)ã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Xianlu L Peng ; Ian C McCabe ; Jen Jen YehSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCancer-associated fibroblast (CAF) heterogeneity within pancreatic ductal adenocarcinoma (PDAC) has been previously assessed through single-cell RNA sequencing (scRNAseq) to discover distinct CAF populations such as myCAFs and iCAFs. While useful as a biological framework, no studies have conclusively and robustly demonstrated a correlation of CAF subpopulations with clinical prognosis or therapy response. We define restraining (rest) and promoting (pro) CAFs in patient samples that are both prognostic and predictive of therapy response in disparate tumor types. Using a single sample classifier, DeCAF, we uncover distinct clinical and spatial interactions between pro- and restCAF subtypes and basal-like and classical tumor subtypes that support tumor stroma crosstalk where basal-like tumors are enriched in proCAFs and classical tumors are enriched in restCAFs. Finally, we find striking differences in the immune contexture of pro- and restCAF tumors where restCAF dominant tumors are enriched in patients who respond to immune checkpoint inhibition (ICI) in two large clinical trials, and proCAF dominant tumors are enriched in patients who respond to myeloid inhibition. This work is the first to define CAF subtypes that are clinically robust, prognostic, predictive of immunotherapy response, and associate with tumor molecular subtype.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310957)

**6.** â­ **GSE313840 å•ç»†èƒæµ‹åºæ­ç¤ºæŸ¯è¨å¥‡ç—…æ¯’ A6 ç›¸å…³æ‰‹è¶³å£ç—…åœ¨å„¿ç«¥ä¸­çš„å…ç–«ç‰¹å¾**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€sequencingã€single-cell
- ğŸ“ **æè¿°**ï¼šContributors : Meng Zhang ; Huiling Deng ; Chenrui Liu ; Na Huang ; Ling He ; Yaping LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHand, foot, and mouth disease (HFMD) is a clinically significant pediatric infection with potential neurological complications, and coxsackievirus A6 (CA6) is increasingly recognized as a predominant causative agent. We identified significant alterations in immune cell composition and amino acid metabolism during disease progression through an integrated multiomics analysis of pediatric patients with CA6-associated HFMD. Single-cell RNA sequencing revealed dynamic changes in peripheral blood mononuclear cell populations, particularly in CD4+ naÃ¯ve T cells, neutrophils, and CD16- monocytes.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313840)

**7.** â­ **GSE310918 åˆ©ç”¨è„‚è´¨é©±åŠ¨çš„å…ç–«ä»£è°¢é€šè·¯å¢å¼ºå¤§ç½‘è†œè½¬ç§»ç˜¤çš„å…ç–«æ²»ç–—æ•ˆæœ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€metabolicã€regex:immuno(logy|therapy|suppression)
- ğŸ“ **æè¿°**ï¼šContributors : Meggy Suarez-Carmona ; Mareike Hampel ; Xin-Wen Zhang ; Alexandra PÃ¶chmann ; Silke A Grauling-Halama ; Nektarios A Valous ; Pornpimol Charoentong ; Dyke Ferber ; Jannis Wissfeld ; Alicia HÃ¶flich ; Stanislas Goriely ; AurÃ©lie Detavernier ; Abdulkader Azouz ; Anthony Rongvaux ; Sven Zukunft ; Ingrid Fleming ; JÃ¼rgen G Okun ; Vickie Baracos ; Mathias HeikenwÃ¤lder ; Laurence Zitvogel ; Xinyi Xu ; Chenqi Xu ; Michael Volkmar ; Daniel Schraivogel ; Lars Steinmetz ; Junzo Hamanishi ; Masaki Mandai ; Mathias Gaida ; Theresa Mokry ; Johanna NattenmÃ¼ller ; Oliver Sedlaczek ; Nanna MonjÃ© ; Roxanna Schwab ; Annette Hasenburg ; Regina Johanna Boger ; Frederik MarmÃ© ; Athanasios Mavratzas ; Sarah Schott ; Niels HalamaSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusDespite the potential of immune checkpoint blockade (ICB) in epithelial ovarian carcinoma (EOC), its clinical efficacy remains limited. Our study investigates the immuno-metabolic landscape of omental metastases to identify therapeutic targets. Using patient-derived explants (PDEs), we demonstrate that lipid-rich omental environments preserve effector T cell function, while lipid processing in tumor-associated macrophages (TAMs) induces oxidative stress and immune suppression. Targeting lipid metabolism via CCR5 inhibition (e.g., maraviroc) or anti-CD36 treatment reprograms TAMs, restores T cell activity, and enhances anti-tumor immunity. These findings reveal a metabolic-inflammatory axis that can be modulated to improve ICB outcomes in EOC.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310918)

**8.** **GSE311789 DeCAFé‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³»ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€regex:immuno(logy|therapy|suppression)
- ğŸ“ **æè¿°**ï¼šSeries Type : Other ; Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311789)

**9.** **GSE288652 ç»“è‚ ä½çº§åˆ«å’Œé«˜çº§åˆ«è…ºç˜¤çš„å…¨åŸºå› ç»„DNAç”²åŸºåŒ–**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šgenomeã€methylation
- ğŸ“ **æè¿°**ï¼šContributors : Alexis Overs ; Jean-Paul Feugeas ; Zohair Selmani ; Paul Peixoto ; Eric Hervouet ; ChloÃ© Molimard ; Laurent Arnould ; FrÃ©dÃ©ric Bibeau ; Jules DurandSeries Type : Methylation profiling by arrayOrganism : Homo sapiensIntroduction: The dynamics of colorectal epigenetics during early carcinogenesis remain undocumented. In this study, we explore the DNA methylation dynamics in colorectal cancer oncogenesis from non-tumor colon tissues to low-grade, high-grade adenoma and adenocarcinoma. Methods: The methylome of 13 low-grade and 19 high-grade colorectal adenomas was determined using the EPIC v1 Human Methylation Beadchip. These methylation profiles were complemented with the methylomes of 206 non-tumor colon and 24 colon adenocarcinomas from GSE149282, GSE132804 series and the HCMI study. Differentially methylated CpG were identified by Student's t-test and used to monitor the evolution of the colon methylome during carcinogenesis. The differentially methylated promoters were used to infer the associated biological process using gene ontology. Results: 4.9% of the colon methylome is significantly altered (p < 10-4) during carcinogenesis with two thirds corresponding to DNA demethylation. 56.6% of the methylation changes occurs at the transition from non-tumor colon tissues to low-grades adenomas. 18.2% of the DNA methylation changes are transitory during low-grade and/or high-grade adenomas. The biological pathways sensory perception of odor and stimulus were early unmethylated, nervous system development and homophilic cell adhesion were early methylated, and chemical synaptic transmission and cell adhesion were transiently methylated. Conclusion: This study provides insight into the dynamics of colonic epigenetics during carcinogenesis, with early DNA methylation changes in the low-grade adenomas associated with transient DNA methylation changes. However, the causality of these changes remains to be elucidated.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288652)

**10.** **GSE311611 åŒæ—¶é¶å‘ KRAS å’Œ CDK4 å¯ååŒè¯±å¯¼èƒ°è…ºç™Œç»†èƒæŒä¹…ç”Ÿé•¿åœæ»**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€KRAS
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusMutant Ras oncoproteins, particularly KRAS, are among the most prevalent drivers of cancer. Small-molecule KRAS inhibitors have emerged as promising cancer therapeutics, yet resistance development remains a major hurdle. To overcome this challenge, we explored rational combination strategies aimed at enhancing therapeutic efficacy and durability. We show that the KRAS-G12C inhibitor Sotorasib synergizes with the CDK4/6 inhibitor Palbociclib to eliminate pancreatic ductal adenocarcinoma (PDAC) cells and organoids harboring KRAS-G12C mutations. This synergy was especially pronounced following drug washout, indicating a durable cellular response. Similar synergistic effects were observed in non-small-cell lung cancer (NSCLC) cells. Additionally, the KRAS-G12D inhibitor MRTX1133 cooperated with Palbociclib to suppress KRAS-G12D-mutant PDAC cells. Mechanistically, the combinations induced sustained cell cycle arrest, marked by reduced RB phosphorylation, decreased E2F1 expression, and increased levels of CDKN1B/p27. Deletion of CDKN1B largely reversed the growth-inhibitory effect, highlighting its essential role in mediating the observed synergy. In an orthotopic, immunocompetent mouse model of PDAC, MRTX1133 significantly delayed tumor growth and extended survival; however, despite its ability to suppress RB phosphorylation, Palbociclib failed to enhance these effects. This might be due to increased tumor vascularization upon Palbociclib treatment, as revealed by single cell RNA sequencing. In summary, our findings demonstrate the therapeutic potential of enhancing cell cycle restriction point activation in KRAS inhibitor-based therapies, while emphasizing the importance of precisely adjusting the drug combinations to the in vivo situation.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311611)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 28 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** â­ **ä¸€ç§éšè—çš„Tç»†èƒå¼€å…³å¯èƒ½ä½¿ç™Œç—‡å…ç–«ç–—æ³•å¯¹æ›´å¤šäººæœ‰æ•ˆã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€T cellã€regex:immuno(logy|therapy|suppression)
- ğŸ“ **æè¿°**ï¼šScientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some cancers and how it could be improved for others.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2025/12/251218074429.htm)

**2.** **SARS-CoV-2æ„ŸæŸ“æ”¹å˜è‚ºç»†èƒlncRNAçš„RNAç”²åŸºåŒ–**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmethylation
- ğŸ“ **æè¿°**ï¼šAltered m6A methylation detected by RNA sequencing in lung cell lncRNAs, including UCA1, GAS5 and NORAD, may reshape antiviral responses during SARS-CoV-2 infection...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/sars-cov-2-infection-alters-rna-methylation-in-lung-cell-lncrnas/)

**3.** **Hummingbird Diagnosticså…¬å¸å‘è¡¨äº†å…³äºæ¶²ä½“æ´»æ£€ä¸­RNAç”Ÿç‰©æ ‡å¿—ç‰©ç”²åŸºåŒ–çš„ç ”ç©¶æŠ¥å‘Š**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmethylation
- ğŸ“ **æè¿°**ï¼šRNA sequencing using nanopore technology reveals small RNA methylation signatures in blood, highlighting RNA modifications as a complementary biomarker layer for more sensitive lung cancer liquid biopsies...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/hummingbird-diagnostics-publishes-study-on-rna-biomarker-methylation-in-liquid-biopsies/)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| single-cell | 7 |
| sequencing | 6 |
| regex:immuno(logy|therapy|suppression) | 6 |
| methylation | 5 |
| tumor | 5 |
| RNA-seq | 4 |
| cardiac | 4 |
| cancer | 4 |
| transcriptomics | 2 |
| genome | 2 |
| aging | 2 |
| epigenetic | 2 |
| transcriptome | 2 |
| inflammation | 2 |
| carcinoma | 1 |
| scRNA | 1 |
| spatial | 1 |
| spatial transcriptomics | 1 |
| macrophage | 1 |
| pathway | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (28æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE299798 ESR1 çš„æ¿€æ´»çªå˜å¯¼è‡´å…ç–«æŠ‘åˆ¶æ€§ä¹³è…ºè‚¿ç˜¤å¾®ç¯å¢ƒçš„å½¢æˆã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299798)
- [GSE294907 ç»´æŠ¤åŸºå› ç»„å®Œæ•´æ€§ï¼šPoloæ ·æ¿€é…¶Cdc5å’Œç£·é…¸é…¶Cdc14åè°ƒæ‹“æ‰‘å¼‚æ„é…¶IIä»‹å¯¼çš„æœ‰ä¸åˆ†è£‚é“¾ç¯è§£ç¦»](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294907)
- [GSE314368 ç»“ç›´è‚ ç™Œè¯±å‘æ¶ç—…è´¨å‘ç”Ÿå’Œå‘å±•è¿‡ç¨‹ä¸­éª¨éª¼è‚Œç”²åŸºåŒ–ç»„-è½¬å½•ç»„çš„ç´Šä¹±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314368)
- [GSE303450 äººç±»å”¾æ¶²è…ºå’Œç±»å™¨å®˜çš„å•ç»†èƒRNAæµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303450)
- [GSE314110 é€šè¿‡AAV2/8ä»‹å¯¼é€’é€äººç±»ç™¾å²è€äººç›¸å…³SIRT6 N308K/A313Sï¼Œè°ƒæ§è‚ç»†èƒç™Œç»†èƒçš„ä¾µè¢­æ€§è½¬å½•](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314110)
- [GSE314066 è¿åŠ¨å¹²é¢„å‰åäººç±»ç²ªä¾¿å¾®ç”Ÿç‰©ç¾¤çš„16S rRNAåŸºå› æµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314066)
- [GSE301845 è…±ç”Ÿè›‹ç™½C+è‚Œæˆçº¤ç»´ç»†èƒé€šè¿‡ä¿ƒè¿›ç¥ç»-å·¨å™¬ç»†èƒç›¸äº’ä½œç”¨åŠ å‰§è¡€ç®¡å†…è†œå¢ç”Ÿ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301845)
- [GSE285475 å†…çš®è½¬å½•å› å­ EB å¯æŠµæŠ—é˜¿éœ‰ç´ è¯±å¯¼çš„å†…çš®æ¯’æ€§å’Œå¿ƒè„åŠŸèƒ½éšœç¢](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285475)
- [GSE262611ï¼šç”¨PI3K/AKT/mTORé€šè·¯æŠ‘åˆ¶å‰‚å¤„ç†çš„MPFRç»†èƒçš„å¾®é˜µåˆ—åŸºå› è¡¨è¾¾æ•°æ®ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262611)
- [GSE237200 å†…çš®è½¬å½•å› å­ EB å¯æŠµæŠ—é˜¿éœ‰ç´ è¯±å¯¼çš„å†…çš®æ¯’æ€§å’Œå¿ƒè„åŠŸèƒ½éšœç¢](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237200)
- [GSE287235 E8.75 é‡ç”Ÿå‹å’Œ Nr6a1 åŸºå› æ•²é™¤å°é¼ èƒšèƒçš„å¤šç»„å­¦ ATAC + åŸºå› è¡¨è¾¾æµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287235)
- [GSE287129 ä¸åŒçš„æŸ“è‰²è´¨è°ƒèŠ‚å› å­ä¸‹è°ƒå‡æ•°åˆ†è£‚è½´è›‹ç™½æ²‰ç§¯å’ŒæŸ“è‰²ä½“æœ«ç«¯çš„ DNA æ–­è£‚è¯±å¯¼ [ChIP-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287129)
- [GSE287127 ä¸åŒçš„æŸ“è‰²è´¨è°ƒèŠ‚å› å­ä¸‹è°ƒå‡æ•°åˆ†è£‚è½´è›‹ç™½æ²‰ç§¯å’ŒæŸ“è‰²ä½“æœ«ç«¯çš„ DNA æ–­è£‚è¯±å¯¼ [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287127)
- [GSE230046 äººç±»å¤šèƒ½å¹²ç»†èƒæ¥æºçš„èƒè‚ç±»å™¨å®˜ä¸­è‚é€ è¡€è°±ç³»çš„è½¬å½•ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230046)
- [GSE314256 è¿ç»­ä½å¼ºåº¦è¶…å£°é€šè¿‡ä¸‹è°ƒç‚ç—‡å’Œä¿ƒè¿› M2 æ ·æ ‡å¿—ç‰©æ¥å½±å“ M1 å·¨å™¬ç»†èƒçš„è½¬å½•ç»„è°±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314256)
- [GSE296724 RNA-seq åˆ†æé‡ç”Ÿå‹å’Œ Oxsr1 æ•²é™¤ HEK293T ç»†èƒçš„åŸºå› è¡¨è¾¾è°±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296724)
- [GSE278465 NFÎºB1ç¼ºé™·ä¸Flt3é«“ç³»ç™½è¡€ç—…ç›¸å…³ï¼Œå¹¶é€šè¿‡RelA:p52å’ŒSOD2è¡¨è¾¾å¤±è°ƒå¢å¼ºç»†èƒè‡ªæˆ‘æ›´æ–°èƒ½åŠ›](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278465)
- [GSE314114 è°ƒæ§æ€§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨çš„å•ç»†èƒå®šä½ IV](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314114)
- [GSE313521 å¤šæ¬¡å¿ƒè‚Œå†…æ³¨å°„è„å¸¦è¡€å•æ ¸ç»†èƒï¼ˆUCB-MNCsï¼‰åå¿ƒè„ä¿®å¤çš„ç‹¬ç‰¹è½¬å½•ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313521)
- [GSE310767 ä½æ°´å¹³è¿·èµ°ç¥ç»åˆºæ¿€å¯¹å‹åŠ›è´Ÿè·è¿‡é‡è¯±å‘çš„å¿ƒåŠ›è¡°ç«­ä¸­å¿ƒè„é‡å¡‘å½±å“çš„è½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310767)
- [GSE299431 è½¬å½•ç»„å­¦ç ”ç©¶ HeLa ç»†èƒä¸­ DNAJC15 å’Œ DNAJC19 çš„æ•²ä½](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299431)
- [GSE296495 å•ç»†èƒè°ƒæ§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨å›¾è°±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296495)
- [GSE296493 å•ç»†èƒè°ƒæ§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨å›¾è°± III](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296493)
- [GSE296492 å•ç»†èƒè°ƒæ§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨å›¾è°± II](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296492)
- [GSE296491 è°ƒæ§æ€§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨çš„å•ç»†èƒå®šä½ I](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296491)
- [GSE287810 iPSCè¡ç”Ÿçš„è§’è´¨å½¢æˆç»†èƒç”¨äºç ”ç©¶ç‰¹åº”æ€§çš®ç‚çš„è¡¨çš®ç¼ºé™·[æ‰¹é‡RNAæµ‹åº]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287810)
- [GSE285002 ç–«è‹—é€’é€å¹³å°å½±å“åŸºäºè¡€å‡ç´ çš„æµæ„Ÿç–«è‹—åœ¨çŒªä½“å†…çš„å¼‚æºä¿æŠ¤ä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285002)
- [GSE277703 LOXL2 è¯†åˆ«å‡ºä¸ç‚ç—‡ç›¸å…³çš„è‚Œæˆçº¤ç»´ç»†èƒï¼Œå¯é¢„æµ‹è‚¾ç§»æ¤åŠŸèƒ½éšœç¢å’Œçº¤ç»´åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277703)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-19 21:36*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*